REPL · XBRL financial data

Replimune Group financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (REPL's year ends in late March)

In millions of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Research and development	57	80	127	175	189	221
Selling, general and administrative	—	—	—	—	72	99
General and administrative	23	39	51	60	72	—
Total operating expenses	80	118	177	235	262	320
Operating income (loss)	(80)	(118)	(177)	(235)	(262)	(320)
Interest expense	1	0	2	4	6	7
Other income (expense)	(1)	(1)	(6)	1	(0)	(1)
Income tax expense (benefit)	0	0	0	0	0	(1)
Net income (loss)	(81)	(118)	(174)	(216)	(247)	(314)
Earnings per share, basic USD per share	(1.75)	(2.26)	(2.99)	(3.24)	(3.07)	(3.38)
Earnings per share, diluted USD per share	(1.75)	(2.26)	(2.99)	(3.24)	(3.07)	(3.38)
Weighted average shares, basic millions of shares	46	52	58	67	81	93
Weighted average shares, diluted millions of shares	46	52	58	67	81	93

Fiscal years (REPL's year ends in late March)

In millions of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Cash and cash equivalents	183	106	147	74	111	209
Short-term investments	294	290	437	346	373	60
Inventory	—	—	—	—	—	0
Prepaid and other current assets	4	5	6	8	8	9
Total current assets	484	404	593	434	496	279
Property and equipment, net	7	8	7	10	14	13
Right-of-use asset	6	6	5	5	4	3
Total assets	543	461	647	488	551	332
Accounts payable	2	4	5	3	12	7
Total current liabilities	15	21	34	40	62	58
Long-term debt	—	0	29	45	46	83
Lease liability, non-current	5	5	4	4	3	2
Total liabilities	44	50	91	113	135	166
Accumulated deficit	(193)	(311)	(485)	(701)	(949)	(1,263)
Total stockholders' equity	499	411	555	375	416	166
Total liabilities and equity	543	461	647	488	551	332
Common shares outstanding (cover page) millions of shares	47	49	58	61	77	84

Fiscal years (REPL's year ends in late March)

In millions of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Net income (loss)	(81)	(118)	(174)	(216)	(247)	(314)
Stock-based compensation	12	24	28	34	35	32
Depreciation and amortization	2	2	2	3	4	3
Net cash from operating activities	(61)	(82)	(128)	(185)	(192)	(280)
Purchases of property and equipment	2	2	2	—	—	—
Net cash from investing activities	(189)	(2)	(143)	97	(24)	311
Proceeds from issuing common stock	286	0	150	0	156	—
Proceeds from long-term debt	—	0	28	15	0	35
Repayments of long-term debt	10	0	—	—	—	—
Net cash from financing activities	372	7	311	16	252	66
Net change in cash	123	(77)	41	(72)	37	98

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Replimune Group	308	not reported	(48)*	94.8M	5.0 quarters	Q2 FY27 10-QSep 30, 2026
Heron Therapeutics	21	not reported	(2.2)*	189.9M	19.3 quarters	Q2 FY26 10-QJun 30, 2026
Aldeyra Therapeutics	45	not reported	(4.6)*	60.3M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Sagimet Biosciences	166	not reported	(11)*	not reported	21.6 quarters	Q2 FY26 10-QJun 30, 2026
Annexon	199	not reported	(48)*	not reported	4.4 quarters	Q2 FY26 10-QJun 30, 2026
Lifecore Biomedical	23	25	6.9*	37.9M	—	Q3 FY26 10-QSep 30, 2026
Precigen	15	74	12*	358.5M	—	Q3 FY26 10-QSep 30, 2026
DBV Technologies	166	1.6	(52)*	314.4M	3.2 quarters	Q3 FY26 10-QSep 30, 2026
SELLAS Life Sciences Group	138	not reported	(7.6)*	201.9M	18.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.